NORTHPOINTE BANCSHARES INC Q2 FY2023 earnings call

• Raj Kannan outlined strategic pillars: rapidly advance oncology assets (uliledlimab, givastomig) globally, maintain strong balance sheet, and establish a US-based global biotech model.
• John Hayslip provided clinical updates: uliledlimab showed promising Phase 1b/2 results in NSCLC, givastomig has encouraging monotherapy efficacy in gastric cancer, eftansomatropin alfa had positive Phase 3 results in growth hormone deficiency, felzartamab and lemzoparlimab are in development for China market.
• Richard Yeh reviewed financial results for H1 2023, including revenue, expenses, and cash position.

Total revenue for the first six months of 2023 was $2.7 million compared with $7.7 million for the same period in 2022. Revenue consisted of revenues from strategic collaboration with AbbVie and supply of investigational products. Cash, cash equivalents, restricted cash and short-term investments as of June 30, 2023, were RMB3 billion (approximately $414.6 million), down from $489 million as of December 31, 2022. Research and development expenses for the first half of 2023 were $61.6 million vs. $67.6 million in 2022, primarily due to reduced payroll and share-based compensation. Administrative expenses were $33.8 million vs. $54.1 million in 2022, due to lower payroll and professional services expenses.

• Plan to submit an IND for uliledlimab in combination with chemotherapy and checkpoint inhibitors in H1 2024.
• Intend to initiate a Phase 1b dose escalation study for givastomig in H1 2024.
• Eftansomatropin alfa plans to submit BLA in China in 2024.
• Maintain strong cash position to support strategic initiatives and streamline spend for key programs.

• Forward-looking statements subject to risks and uncertainties beyond the company's control, including new risk factors emerging over time that could materially affect actual results.
• Risks detailed in SEC filings, with no guarantee future performance aligns with forward-looking statements.

Q: Comment on the safety profile of eftansomatropin alfa from the Phase 3 trial and timeline for regulatory approval and commercial launch?

A: John Hayslip stated the safety profile was comparable to Norditropin in the trial, and Andrew Zhu mentioned plans to submit BLA in China in 2024.

Q: Thoughts on the potential of givastomig capturing a broader Claudin expression range with zolbetuximab potentially approved?

A: John Hayslip noted givastomig showed efficacy in patients with lower Claudin 18.2 expression and is optimistic about benefiting a broader patient group.

Q: How does the outcome of magrolimab's ENHANCE trial influence lemzoparlimab's clinical strategy?

A: Raj Kannan said it's premature to decide, but the company continues enrolling in Phase 3 trial and will review interim data and class data to inform decisions.

Q: Elaboration on the company's vision for I-Mab and timeline to reach objectives?

A: Raj Kannan stated 24-month timeline with key catalysts expected by end of 2025 to enhance shareholder value.

Q: Comments on pricing of eftansomatropin alfa and comparison to competitors?

A: Raj Kannan said it's premature to comment on price but emphasized competitive pricing for the product.